| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9a11085f218d538b6bb5485115d51e7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ab766eec8d5504ebfd51ef2114bb5bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f99ef9210579d7c3175b7eaa0d44d7e1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2015-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbb38205a9150879d8e250ddee706b35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f45f8b0dbd49a4008eb05eb27eb4c387 |
| publicationDate |
2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10080748-B2 |
| titleOfInvention |
Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system |
| abstract |
The present invention provides methods of attenuating or preventing brain injury mediated damage in the central nervous system by attenuating or preventing leukotriene-mediated events following a brain injury or long-term neuroinflammation after brain injury, in Alzheimer's disease, multiple sclerosis, stroke, and post-traumatic stress disorder. The methods comprise administering at least one 5-lipoxygenase activating protein (FLAP) inhibitor either before or after the brain injury. The method finds use in the treatment of traumatic brain injury (TBI), stroke, multiple sclerosis, Alzheimer's disease, post-traumatic stress disorder and other brain injuries associated with production of leukotrienes in the central nervous system. Preferably the FLAP inhibitor is administered intranasally and preferably for certain high risk individuals prophylactically prior to any potential brain injury event. |
| priorityDate |
2014-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |